APA (7. basım) Alıntı

Klinder, A., Waletzko-Hellwig, J., Sellin, M., Seyfarth-Sehlke, A., Wolfien, M., Prehn, F., . . . Jonitz-Heincke, A. (2022). Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts. MDPI AG.

Chicago Style (17. basım) Atıf

Klinder, Annett, Janine Waletzko-Hellwig, Marie-Luise Sellin, Anika Seyfarth-Sehlke, Markus Wolfien, Franziska Prehn, Rainer Bader, ve Anika Jonitz-Heincke. Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts. MDPI AG, 2022.

MLA (9th ed.) Atıf

Klinder, Annett, et al. Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts. MDPI AG, 2022.

Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..